The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis. Investigators in South Korea demonstrated the benefit in a ...
PORTSMOUTH, N.H., July 10, 2025 /PRNewswire/ -- Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie ...
For permission requests, please contact NEJM Reprints at [email protected] ...
The prostatic urethral stent for relief of lower urinary tract symptoms from benign prostatic hyperplasia (BPH) was tested in the ProVide trial.
Urinary tract infections are common in both males and females, with causes ranging from stones and strictures in males to ...
The FDA has granted approval to Urotronic Inc. for its Optilume urethral drug-coated balloon (DCB) for the treatment of male urethral strictures. The device inhibits new scar tissue growth that may ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback